EPIK-O/ENGOT-ov61 主要分析:阿培利司联合奥拉帕利对比化疗用于无 BRCA 突变的铂耐药或铂难治性高级别浆液性卵巢癌
EPIK-O 是一项开放标签 III 期试验,将无胚系或已知体细胞 BRCA 突变的铂耐药/铂难治性高级别浆液性卵巢癌患者 1:1 随机分配至阿培利司 200 mg 每日一次联合奥拉帕利 200 mg 每日两次组或医生选择化疗组。主要终点盲法独立中心评审(BIRC)评估的无进展生存期(PFS)未达到,阿培利司联合奥拉帕利组的中位 PFS 为 3.6 个月,化疗组为 3.9 个月(HR 1.14,95%CI 0.88 至 1.48;单侧 P=0.84)。
要点
- 阿培利司联合奥拉帕利对比化疗未改善铂耐药/铂难治性无 BRCA 突变高级别浆液性卵巢癌的 PFS。
- 联合组与化疗组的中位 PFS 分别为 3.6 个月和 3.9 个月(HR 1.14,95%CI 0.88 至 1.48;单侧 P=0.84)。
- 联合组的安全性特征与各单药已知安全性一致,未观察到新的或非预期不良事件。
核心结论
- EPIK-O 的主要目标 PFS 改善未达到。
- 未观察到新的或非预期不良事件。
- 生物标志物分析为阿培利司联合奥拉帕利的应答者提供了新见解。
研究设计与样本
- EPIK-O 是一项开放标签 III 期试验,将铂耐药/铂难治性高级别浆液性卵巢癌且无胚系或已知体细胞 BRCA 突变的患者 1:1 随机分配。
- 联合组方案为阿培利司 200 mg 每日一次加奥拉帕利 200 mg 每日两次;医生选择化疗(TPC)为紫杉醇 80 mg/m2 每周一次或聚乙二醇脂质体多柔比星 40-50 mg/m2 每 28 天一次。
- 患者既往接受过 1-3 线全身治疗;既往要求使用过贝伐珠单抗(除非有禁忌);允许既往使用聚腺苷二磷酸核糖聚合酶抑制剂。
- 主要终点为盲法独立中心评审(BIRC)按 RECIST 1.1 评估的无进展生存期(PFS)。
- 共纳入 358 例患者(阿培利司联合奥拉帕利组 n=180,TPC 组 n=178),中位随访时间为 9.3 个月。
主要发现
- 数据截止日期为 2023 年 4 月 21 日,阿培利司联合奥拉帕利组和 TPC 组分别有 33 例(18.3%)和 30 例(16.9%)患者仍在接受治疗。
- BIRC 评估的中位 PFS 在阿培利司联合奥拉帕利组为 3.6 个月,TPC 组为 3.9 个月(HR 1.14,95%CI 0.88 至 1.48;单侧 P=0.84)。
- 客观缓解率(ORR)在阿培利司联合奥拉帕利组为 15.6%(95%CI 10.6% 至 21.7%),TPC 组为 13.5%(95%CI 8.8% 至 19.4%)。
- 中位总生存期(OS)在阿培利司联合奥拉帕利组为 10.0 个月,TPC 组为 10.6 个月(HR 1.22;95%CI 0.87 至 1.71)。
- 阿培利司联合奥拉帕利的安全性特征与各单药已知安全性一致。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with platinum-resistant/platinum-refractory high-grade serous ovarian cancer (HGSOC) without a BRCA mutation have poor prognosis and limited treatment options. We report efficacy and biomarker data from EPIK-O, which investigated alpelisib + olaparib versus single-agent chemotherapy in these patients. PATIENTS AND METHODS: EPIK-O was an open-label, phase III trial that randomly assigned patients with platinum-resistant/platinum-refractory HGSOC with no germline or known somatic BRCA mutation 1:1 to alpelisib 200 mg once daily + olaparib 200 mg twice daily or treatment of physician's choice (TPC; paclitaxel 80 mg/m2 once weekly or pegylated liposomal doxorubicin 40-50 mg/m2 once every 28 days). Patients had 1-3 previous systemic therapies. Previous bevacizumab was required (unless contraindicated); previous poly(adenosine diphosphate-ribose) polymerase inhibitors were allowed. Primary end point was progression-free survival (PFS) per RECIST 1.1 (blinded independent review committee [BIRC]). Secondary efficacy end points included overall response rate (ORR; per BIRC), duration of response (per BIRC), and overall survival (OS; key secondary end point). RESULTS: A total of 358 patients (alpelisib + olaparib [n = 180], TPC [n = 178]) were included. The median follow-up time was 9.3 months. At data cutoff (April 21, 2023), 33 (18.3%) and 30 (16.9%) patients remained on treatment with alpelisib + olaparib and TPC, respectively. The median PFS (BIRC) was 3.6 versus 3.9 months (hazard ratio [HR], 1.14 [95% CI, 0.88 to 1.48]; one-sided P = .84) for alpelisib + olaparib versus TPC. The ORR was 15.6% (95% CI, 10.6% to 21.7%) versus 13.5% (95% CI, 8.8% to 19.4%). The median OS was 10.0 versus 10.6 months (HR, 1.22; 95% CI, 0.87 to 1.71). The safety profile of alpelisib + olaparib was consistent with that observed for the individual agents. CONCLUSION: The primary objective, PFS improvement, was not met in EPIK-O. No new or unexpected adverse events were observed. Biomarker analyses provided new insights for responders to alpelisib + olaparib.
引用
- Konstantinopoulos PA, Kim JW, Freyer G, et al. Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation. J Clin Oncol. 2025. PMID: 40700681. doi:10.1200/JCO-25-00225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。